Yixiang Sun - Search Results

Year	Number of Results
2009	2
2014	1
2015	1
2017	1
2018	1
2020	3
2021	6
2022	17
2023	6

1

Therapeutic potential of targeting LSD1/ KDM1A in cancers.

Zhang X, Wang X, Wu T, Yin W, Yan J, Sun Y, Zhao D. Zhang X, et al. Among authors: sun y. Pharmacol Res. 2022 Jan;175:105958. doi: 10.1016/j.phrs.2021.105958. Epub 2021 Oct 28. Pharmacol Res. 2022. PMID: 34718134 Review.

2

Design, synthesis, and biological evaluation of potent FAK-degrading PROTACs.

Qin Q, Wang R, Fu Q, Zhang G, Wu T, Liu N, Lv R, Yin W, Sun Y, Sun Y, Zhao D, Cheng M. Qin Q, et al. Among authors: sun y. J Enzyme Inhib Med Chem. 2022 Dec;37(1):2241-2255. doi: 10.1080/14756366.2022.2100886. J Enzyme Inhib Med Chem. 2022. PMID: 35978496 Free PMC article.

3

Identification of novel indole derivatives as highly potent and efficacious LSD1 inhibitors.

Zhang X, Sun Y, Huang H, Wang X, Wu T, Yin W, Li X, Wang L, Gu Y, Zhao D, Cheng M. Zhang X, et al. Among authors: sun y. Eur J Med Chem. 2022 Sep 5;239:114523. doi: 10.1016/j.ejmech.2022.114523. Epub 2022 Jun 10. Eur J Med Chem. 2022. PMID: 35732082

4

Design, synthesis, and biological evaluation of coumarin analogs as novel LSD1 inhibitors.

Sun Y, Lv R, Wu T, Zhang X, Sun Y, Yan J, Zhang Z, Zhao D, Cheng M. Sun Y, et al. Arch Pharm (Weinheim). 2022 Feb;355(2):e2100311. doi: 10.1002/ardp.202100311. Epub 2021 Dec 4. Arch Pharm (Weinheim). 2022. PMID: 34862974

5

Rational drug design to explore the structure-activity relationship (SAR) of TRK inhibitors with 2,4-diaminopyrimidine scaffold.

Wu T, Qin Q, Liu N, Zhang C, Lv R, Yin W, Sun Y, Sun Y, Wang R, Zhao D, Cheng M. Wu T, et al. Among authors: sun y. Eur J Med Chem. 2022 Feb 15;230:114096. doi: 10.1016/j.ejmech.2021.114096. Epub 2022 Jan 3. Eur J Med Chem. 2022. PMID: 35007864

6

Design, synthesis, and evaluation of novel 3,4-isoxazolediamide derivatives for the combination treatment of azole-resistant candidiasis.

Liu L, Sun Y, Gao Z, Yin W, Jiang H, Wu T, Sun Y, Qin Q, Zhao D, Cheng M. Liu L, et al. Among authors: sun y. Arch Pharm (Weinheim). 2022 Dec;355(12):e2200266. doi: 10.1002/ardp.202200266. Epub 2022 Aug 27. Arch Pharm (Weinheim). 2022. PMID: 36029272

7

Structure-based discovery of 1-(3-fluoro-5-(5-(3-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)phenyl)-3-(pyrimidin-5-yl)urea as a potent and selective nanomolar type-II PLK4 inhibitor.

Sun Y, Wang L, Sun Y, Wang J, Xue Y, Wu T, Yin W, Qin Q, Sun Y, Wang H, Gao Y, Yang H, Zhao D, Cheng M. Sun Y, et al. Eur J Med Chem. 2022 Dec 5;243:114714. doi: 10.1016/j.ejmech.2022.114714. Epub 2022 Aug 30. Eur J Med Chem. 2022. PMID: 36063666

8

Intermolecular insights into allosteric inhibition of histone lysine-specific demethylase 1.

Zhang X, Sun Y, Zhang Z, Wang H, Wang J, Zhao D. Zhang X, et al. Among authors: sun y. Biochim Biophys Acta Gen Subj. 2021 Nov;1865(11):129990. doi: 10.1016/j.bbagen.2021.129990. Epub 2021 Aug 12. Biochim Biophys Acta Gen Subj. 2021. PMID: 34390793

9

Discovery of quinazoline derivatives CZw-124 as a pan-TRK inhibitor with potent anticancer effects in vitro and in vivo.

Wu T, Qin Q, Lv R, Liu N, Yin W, Hao C, Sun Y, Zhang C, Sun Y, Zhao D, Cheng M. Wu T, et al. Among authors: sun y. Eur J Med Chem. 2022 Aug 5;238:114451. doi: 10.1016/j.ejmech.2022.114451. Epub 2022 May 11. Eur J Med Chem. 2022. PMID: 35617855

10

Design, synthesis, and biological evaluation of 5-aminotetrahydroquinoline-based LSD1 inhibitors acting on Asp375.

Yan J, Gu Y, Sun Y, Zhang Z, Zhang X, Wang X, Wu T, Zhao D, Cheng M. Yan J, et al. Among authors: sun y. Arch Pharm (Weinheim). 2021 Aug;354(8):e2100102. doi: 10.1002/ardp.202100102. Epub 2021 May 13. Arch Pharm (Weinheim). 2021. PMID: 33987875

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results